Form 4: Tonix Pharmaceuticals CEO Acquires 4,000 Shares of Common Stock

Tonix Pharmaceuticals CEO Seth Lederman reports the acquisition of 4,000 shares of common stock at $21.55 per share on May 15, 2025.

Summary

• On May 15, 2025, Seth Lederman, CEO of Tonix Pharmaceuticals Holding Corp., acquired 4,000 shares of common stock.
• The purchase price was $21.55 per share.
• Following the transaction, Mr. Lederman directly owns 4,005 shares of Tonix Pharmaceuticals.
• Mr. Lederman also indirectly owns shares through an IRA account and Lederman & Co.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock acquisition by the CEO. While insider buying can be seen as a positive signal, it's not overwhelmingly so without additional context.

Positives

• The CEO's purchase of shares may signal confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider trading activity, which is common for publicly traded companies. Investors often monitor such filings for signals about management's confidence in the company.

Stakeholder Impact

• The CEO's stock purchase could positively influence shareholder sentiment.

Key Dates

Keywords

Tonix Pharmaceuticals, TNXP, Seth Lederman, CEO, stock acquisition, Form 4, beneficial ownership, common stock